A patent review of SCF E3 ligases inhibitors for cancer:Structural design, pharmacological activities and structure–activity relationship DOI
Jing Zeng,

Zheng Chen,

Yuxin He

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 278, С. 116821 - 116821

Опубликована: Авг. 31, 2024

Язык: Английский

Anticancer and Antioxidant Effects of Bioactive Peptides from Black Soldier Fly Larvae (Hermetia illucens) DOI Open Access
Kwanchanok Praseatsook, Arpamas Vachiraarunwong, Sirinya Taya

и другие.

Nutrients, Год журнала: 2025, Номер 17(4), С. 645 - 645

Опубликована: Фев. 11, 2025

Background: Protein hydrolysates from insects are recognized for their biological activities. Black soldier fly larvae (BSFL) have drawn attention due to antioxidant protein hydrolysates. However, research on bioactive peptides derived these hydrolysates, particularly cancer chemopreventive potential, remains limited. This study aims evaluate the antioxidant, anti-inflammatory, antimutagenic, and anticancer activities of BSFL-derived explore molecular mechanisms. Methods: Alkali-soluble BSFL (ASBP) was extracted hydrolyzed using Alcalase bromelain under optimized conditions. Antioxidant activity assessed via FRAP, ABTS, DPPH assays. The hydrolysate with highest fractionated into weight (MW) groups (>30, 10, <3 kDa). bioactivity evaluated through anti-inflammatory (nitric oxide production in RAW 264.7 cells), antimutagenic (Ames test), (CCK-8 assay HCT 116, COLO205, Cw-2, Caco-2 cells) Mechanistic insights were obtained microarray Western blot analyses. Peptides identified by LC-MS/MS. Results: ASBP-Alcalase (ASBP-AH) showed optimal at 3% (w/w) 4 h. ASBP-AH 30 (MW > kDa) fraction exhibited capacity. In contrast, ASBP-AH3 < 3 significant effects, reduced nitric production, decreased COLO205 cell viability. Treatment its LC50 dose modulated SKP2/p21/cyclin D1 pathways. Mostly composed hydrophobic charged amino acids. Conclusions: exhibit potential as multifunctional agents chemoprevention. vivo studies required clinical applications.

Язык: Английский

Процитировано

3

F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies DOI Creative Commons
Mei Dai, Shimin Chen, Yuanjing Wang

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Июнь 4, 2025

As critical substrate-recognition subunits of the SCF (SKP1-CUL1-F-box) ubiquitin ligase complex, F-box proteins mediate ubiquitination and subsequent degradation specific target proteins, playing pivotal roles in cell cycle regulation, signal transduction (e.g., MAPK NF-κB pathways), immune homeostasis. have dual regulatory functions tumorigenesis escape. On one hand, their expression is dynamically modulated by upstream signaling pathways (including PI3K/AKT Wnt/β-catenin cascades) epigenetic modifications (such as DNA methylation histone acetylation), thereby influencing stability oncogenic factors c-MYC, Cyclin E) or tumor suppressors p53). other directly regulate microenvironments targeting immune-related molecules for degradation, modulating T-cell activation, macrophage polarization, checkpoint functionality (specifically PD-1/PD-L1 axis CTLA-4 signaling). This review systematically summarizes downstream networks with an emphasis on molecular mechanisms immunosuppression. It highlights potential strategies drug resistance combination immunotherapies, while also discussing future research applications development directions proteins. These insights aim to advance novel immunotherapeutic precision cancer treatment.

Язык: Английский

Процитировано

0

Targeting of S-phase kinase associated protein 2 stabilized tumor suppressors leading to apoptotic cell death in squamous skin cancer cells DOI

Abdul Quaiyoom Khan,

Maha Al-Tamimi,

Rasheeda Anver

и другие.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Год журнала: 2024, Номер 1870(7), С. 167286 - 167286

Опубликована: Июнь 12, 2024

Язык: Английский

Процитировано

2

A patent review of SCF E3 ligases inhibitors for cancer:Structural design, pharmacological activities and structure–activity relationship DOI
Jing Zeng,

Zheng Chen,

Yuxin He

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 278, С. 116821 - 116821

Опубликована: Авг. 31, 2024

Язык: Английский

Процитировано

1